Literature DB >> 16546196

A systematic review of LDL apheresis in the treatment of cardiovascular disease.

Jeff Thompsen1, Paul D Thompson.   

Abstract

LDL apheresis is an effective method of lowering low-density lipoprotein (LDL) concentration in patients with familial hypercholesterolemia (FH) who are either refractory to treatment or intolerant of medical therapy. We searched the medical literature through July 2004 using PubMed and Medline and the search terms "LDL apheresis", "cardiovascular", and "disease" to identify apheresis techniques and to evaluate their effects on cardiovascular pathophysiology and clinical outcomes. We conclude that LDL apheresis reduces cardiovascular events in hypercholesterolemic patients and may be an effective treatment for other vascular diseases including cholesterol embolic disease, focal segmental glomerular sclerosis, sudden hearing loss, and age-related macular degeneration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16546196     DOI: 10.1016/j.atherosclerosis.2006.02.030

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  18 in total

Review 1.  Clinical utility gene card for: hyperlipoproteinemia, TYPE II.

Authors:  Ursula Kassner; Marion Wühle-Demuth; Isabelle Missala; Steve E Humphries; Elisabeth Steinhagen-Thiessen; Ilja Demuth
Journal:  Eur J Hum Genet       Date:  2013-11-20       Impact factor: 4.246

2.  Translational lessons from a case of combined heart and liver transplantation for familial hypercholesterolemia 20 years post-operatively.

Authors:  Michael Ibrahim; Ismail El-Hamamsy; Mahmoud Barbir; Magdi H Yacoub
Journal:  J Cardiovasc Transl Res       Date:  2011-09-01       Impact factor: 4.132

3.  Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice.

Authors:  Adam E Mullick; Wuxia Fu; Mark J Graham; Richard G Lee; Donna Witchell; Thomas A Bell; Charles P Whipple; Rosanne M Crooke
Journal:  J Lipid Res       Date:  2011-02-22       Impact factor: 5.922

4.  Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies.

Authors:  Sadik H Kassim; James M Wilson; Daniel J Rader
Journal:  Clin Lipidol       Date:  2010-06

5.  Low-density lipoprotein apheresis: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-11-01

6.  Low-density lipoprotein apheresis as a treatment option for hyperlipidemia.

Authors:  Puja K Mehta; Jefferson Baer; Christine Nell; Laurence S Sperling
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-08

Review 7.  How do you treat patients with myalgia who take statins?

Authors:  Saadi A Siddiqi; Paul D Thompson
Journal:  Curr Atheroscler Rep       Date:  2009-01       Impact factor: 5.113

8.  Plasma LDL cholesterol has no impact on P-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells.

Authors:  Caroline Henrike Storch; Hans-Dieter Klimm; Tilman Heinrich; Walter Emil Haefeli; Johanna Weiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-07-26       Impact factor: 3.000

9.  LDLR promoter variant and exon 14 mutation on the same chromosome are associated with an unusually severe FH phenotype and treatment resistance.

Authors:  Christine L H Snozek; Susan A Lagerstedt; Teck K Khoo; Melvyn Rubenfire; William L Isley; Laura J Train; Linnea M Baudhuin
Journal:  Eur J Hum Genet       Date:  2008-07-23       Impact factor: 4.246

10.  Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia.

Authors:  Kiyohito Arai; Alexina Orsoni; Ziad Mallat; Alain Tedgui; Joseph L Witztum; Eric Bruckert; Alexandros D Tselepis; M John Chapman; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2012-05-24       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.